Literature DB >> 21133893

Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

T T Myöhänen1, J Tenorio-Laranga, B Jokinen, R Vázquez-Sánchez, M J Moreno-Baylach, J A García-Horsman, P T Männistö.   

Abstract

BACKGROUND AND PURPOSE A serine protease, prolyl oligopeptidase (POP) has been reported to be involved in the release of the pro-angiogenic tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Ac-SDKP) from its precursor, 43-mer thymosin β4 (Tβ4). Recently, it was shown that both POP activity and the levels of Ac-SDKP are increased in malignant tumours. The aim of this study was to clarify the release of Ac-SDKP, and test if POP and a POP inhibitor, 4-phenyl-butanoyl-L-prolyl-2(S)-cyanopyrrolidine (KYP-2047), can affect angiogenesis. EXPERIMENTAL APPROACH We used HPLC for bioanalytical and an enzyme immunoassay for pharmacological analysis. Angiogenesis of human umbilical vein endothelial cells was assessed in vitro using a 'tube formation' assay and in vivo using a Matrigel plug assay (BD Biosciences, San Jose, CA, USA) in adult male rats. Moreover, co-localization of POP and blood vessels was studied. KEY RESULTS We showed the sequential hydrolysis of Tβ4: the first-step hydrolysis by proteases to <30-mer peptides is followed by an action of POP. Unexpectedly, POP inhibited the first hydrolysis step, revealing a novel regulation system. POP with Tβ4 significantly induced, while KYP-2047 effectively prevented, angiogenesis in both models compared with Tβ4 addition itself. POP and endothelial cells were abundantly co-localized in vivo. CONCLUSIONS AND IMPLICATIONS We have now revealed that POP is a second-step enzyme in the release of Ac-SDKP from Tβ4, and it has novel autoregulatory effect in the first step. Our results also advocate a role for Ac-SDKP in angiogenesis, and suggest that POP has a pro-angiogenic role via the release of Ac-SDKP from its precursor Tβ4 and POP inhibitors can block this action.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21133893      PMCID: PMC3166694          DOI: 10.1111/j.1476-5381.2010.01146.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  58 in total

1.  Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation.

Authors:  A E Bogden; P Carde; E D de Paillette; J P Moreau; M Tubiana; E Frindel
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP. I. The precise point of the cell cycle sensitive to AcSDKP. Studies on the effect of AcSDKP on GM-CFC and on the possible involvement of T-lymphocytes in AcSDKP response.

Authors:  J P Monpezat; E Frindel
Journal:  Exp Hematol       Date:  1989-12       Impact factor: 3.084

4.  Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.

Authors:  H Peng; O A Carretero; L Raij; F Yang; A Kapke; N E Rhaleb
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

Review 5.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

6.  Formation of acetyl-Ser-Asp-Lys-Pro, a new regulator of the hematopoietic system, through enzymatic processing of thymosin beta 4.

Authors:  M Lenfant; C Grillon; K J Rieger; D Sotty; J Wdzieczak-Bakala
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

7.  A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.

Authors:  Elina M Jarho; Jarkko I Venäläinen; Juhani Huuskonen; Johannes A M Christiaans; J Arturo Garcia-Horsman; Markus M Forsberg; Tomi Järvinen; Jukka Gynther; Pekka T Männistö; Erik A A Wallén
Journal:  J Med Chem       Date:  2004-11-04       Impact factor: 7.446

8.  A common mechanism of action for three mood-stabilizing drugs.

Authors:  Robin S B Williams; Lili Cheng; Anne W Mudge; Adrian J Harwood
Journal:  Nature       Date:  2002-05-16       Impact factor: 49.962

9.  N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo.

Authors:  Dahai Wang; Oscar A Carretero; Xiao-Yi Yang; Nour-Eddine Rhaleb; Yun-He Liu; Tang-Dong Liao; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-07-15       Impact factor: 4.733

10.  Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.

Authors:  Maria A Cavasin; Nour-Eddine Rhaleb; Xiao-Ping Yang; Oscar A Carretero
Journal:  Hypertension       Date:  2004-03-22       Impact factor: 10.190

View more
  26 in total

Review 1.  Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis.

Authors:  Bruce A Corliss; Mohammad S Azimi; Jennifer M Munson; Shayn M Peirce; Walter L Murfee
Journal:  Microcirculation       Date:  2016-02       Impact factor: 2.628

2.  The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase.

Authors:  Nitin Kumar; Pablo Nakagawa; Branislava Janic; Cesar A Romero; Morel E Worou; Sumit R Monu; Edward L Peterson; Jiajiu Shaw; Frederick Valeriote; Elimelda M Ongeri; Jean-Marie V Niyitegeka; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Am J Physiol Renal Physiol       Date:  2016-03-09

3.  A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.

Authors:  T T Myöhänen; M J Hannula; R Van Elzen; M Gerard; P Van Der Veken; J A García-Horsman; V Baekelandt; P T Männistö; A M Lambeir
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

4.  A snapshot of the Ixodes scapularis degradome.

Authors:  Albert Mulenga; Kelly Erikson
Journal:  Gene       Date:  2011-04-28       Impact factor: 3.688

5.  N-acetyl-seryl-aspartyl-lysyl-proline treatment protects heart against excessive myocardial injury and heart failure in mice.

Authors:  Hongmei Peng; Jiang Xu; Xiao-Ping Yang; Kamal M Kassem; Imane A Rhaleb; Ed Peterson; Nour-Eddine Rhaleb
Journal:  Can J Physiol Pharmacol       Date:  2019-04-18       Impact factor: 2.273

Review 6.  Nontraditional roles of angiotensin-converting enzyme.

Authors:  Xiao Z Shen; Frank S Ong; Ellen A Bernstein; Tea Janjulia; Wendell-Lamar B Blackwell; Kandarp H Shah; Brian L Taylor; Romer A Gonzalez-Villalobos; Sebastien Fuchs; Kenneth E Bernstein
Journal:  Hypertension       Date:  2012-02-21       Impact factor: 10.190

Review 7.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

8.  Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors.

Authors:  Timo T Myöhänen; Elisa Pyykkö; Pekka T Männistö; Olli Carpen
Journal:  J Histochem Cytochem       Date:  2012-06-26       Impact factor: 2.479

9.  Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Tamyra D Downs; Patrick A McKee
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

10.  Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent.

Authors:  Peter Serfozo; Jan Wysocki; Gvantca Gulua; Arndt Schulze; Minghao Ye; Pan Liu; Jing Jin; Michael Bader; Timo Myöhänen; J Arturo García-Horsman; Daniel Batlle
Journal:  Hypertension       Date:  2019-12-02       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.